These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19467159)

  • 1. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
    Campbell GR; Loret EP
    Retrovirology; 2009 May; 6():50. PubMed ID: 19467159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection.
    Huigen MC; Kamp W; Nottet HS
    Eur J Clin Invest; 2004 Jan; 34(1):57-66. PubMed ID: 14984439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
    Gupta S; Mitra D
    Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.
    Ensoli B; Moretti S; Borsetti A; Maggiorella MT; Buttò S; Picconi O; Tripiciano A; Sgadari C; Monini P; Cafaro A
    Arch Virol; 2021 Nov; 166(11):2955-2974. PubMed ID: 34390393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
    Kashi VP; Jacob RA; Shamanna RA; Menon M; Balasiddaiah A; Varghese RK; Bachu M; Ranga U
    PLoS One; 2014; 9(12):e114155. PubMed ID: 25531437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.
    Foucault M; Mayol K; Receveur-Bréchot V; Bussat MC; Klinguer-Hamour C; Verrier B; Beck A; Haser R; Gouet P; Guillon C
    Proteins; 2010 May; 78(6):1441-56. PubMed ID: 20034112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV extracellular Tat: myth or reality?
    Loret E
    Curr HIV Res; 2015; 13(2):90-7. PubMed ID: 25439235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.
    Cafaro A; Tripiciano A; Sgadari C; Bellino S; Picconi O; Longo O; Francavilla V; Buttò S; Titti F; Monini P; Ensoli F; Ensoli B
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S13-29. PubMed ID: 26096836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the development of HIV-1 Tat-based vaccines.
    Caputo A; Gavioli R; Ensoli B
    Curr HIV Res; 2004 Oct; 2(4):357-76. PubMed ID: 15544457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET.
    Chiozzini C; Toschi E
    Curr Drug Targets; 2016; 17(1):33-45. PubMed ID: 26302810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Tat protein as a potential AIDS vaccine.
    Goldstein G
    Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
    [No Abstract]   [Full Text] [Related]  

  • 17. Functional roles of HIV-1 Tat protein in the nucleus.
    Musinova YR; Sheval EV; Dib C; Germini D; Vassetzky YS
    Cell Mol Life Sci; 2016 Feb; 73(3):589-601. PubMed ID: 26507246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
    Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
    J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
    Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
    AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.
    Bellino S; Francavilla V; Longo O; Tripiciano A; Paniccia G; Arancio A; Fiorelli V; Scoglio A; Collacchi B; Campagna M; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Rev Recent Clin Trials; 2009 Sep; 4(3):195-204. PubMed ID: 20028332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.